Tag - TSBX

Developments

Turnstone restructures to focus resources on advancing Phase 1 study

Turnstone Biologics (NASDAQ:TSBX) has announced restructuring initiatives that include the strategic prioritization of its pipeline, a 60% workforce reduction, and changes to its leadership team, aimed at focusing...

October 11, 2024

Markets

Leerink starts Turnstone Biologics at MP; PT $13

Leerink Partners initiated coverage of Turnstone Biologics (NASDAQ:TSBX) with a “market perform” rating and $13 price target. The stock closed at $11.73 on Aug. 14. “We see potential in Turnstone’s selected tumor...

August 15, 2023

Tag - TSBX

Turnstone restructures to focus resources on advancing Phase 1 study

Leerink starts Turnstone Biologics at MP; PT $13

General

More